Series D funds drive Paracor HeartNet trial
This article was originally published in Clinica
Paracor Medical, a developer of device-based treatments for heart failure, has closed a series D financing round worth $44.35m. The round was led by new investor Aberdare Ventures; other participants include Montagu Newhall Associates, and existing shareholders Delphi Ventures, Pequot Ventures, InterWest Partners, Alta Partners, DeNovo Ventures, Saratoga Ventures and Palo Alto Investors.
You may also be interested in...
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.